Clinical Trial

Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation

Study acronym: SEMINAL-AF
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The goal of the study is to learn how a weight loss medication called semaglutide, which is used to treat obesity, in addition to standard AF treatment might affect AF, atrial fibrillation severity, and whether it changes the risk of atrial fibrillation recurring after standard AF treatments.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2024-07-11; most recent amendment 2025-11-13.
Status change: Not Yet Recruiting → Recruiting 2025-08-01
Trial Details
NCT Number NCT06499857
Lead Sponsor University of Chicago
Conditions Overweight or Obesity, Atrial Fibrillation
Enrollment 200 participants
Start Date 2025-04-14
Primary Completion 2027-12 (estimated)
Study Completion 2028-06 (estimated)
Updated on ClinicalTrials.gov 2025-11-14